Acute Myeloid Leukemia (AML) in the United States: Primary Insights Into the Patient Experience
September 26, 2024 04:25 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added...
Chronic Lymphocytic Leukemia (CLL) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction
September 26, 2024 04:23 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Chronic Lymphocytic Leukemia (CLL) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been...
U.S. Chronic Myeloid Leukemia (CML) Treatment Awareness & Satisfaction Report - What Medications Have Patients Discussed With Their HCP?
September 26, 2024 04:21 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myeloid Leukemia (CML) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been...
U.S. Myelodysplastic Syndromes (MDS) Patient Insights Report: HCP Treatment Discussions, Treatment Satisfaction & Awareness, Clinical Trial Interest, and Much More
September 26, 2024 04:20 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Myelodysplastic Syndromes (MDS) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been...
AB Science fait aujourd'hui le point sur le programme microtubule AB8939 et en particulier sur la capacité d'AB8939 à générer une réponse sur le réarrangement du gène MECOM
September 26, 2024 02:28 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LE PROGRAMME MICROTUBULE AB8939 ET EN PARTICULIER SUR LA CAPACITÉ D’AB8939 À GÉNÉRER UNE RÉPONSE SUR LE REARRANGEMENT DU GENE MECOM Paris, 26...
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
September 26, 2024 02:28 ET
|
AB Science
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE MICROTUBULE PROGRAM AB8939 AND IN PARTICULAR THE ABILITY OF AB8939 TO GENERATE RESPONSE ON MECOM REARRANGEMENT Paris, 26 September 2024, 8.30am CET...
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
September 18, 2024 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Receives FDA Fast Track Designation for ICT01in Combination with Azacitidine and Venetoclaxin First-Line Acute Myeloid Leukemiafor Patients Unfit for Induction Chemotherapy Treatment ICT01,...
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
September 05, 2024 16:01 ET
|
Vor Biopharma
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with...
Two Life-Saving Marrow Donors Meet Their Transplant Recipients at Gift of Life Marrow Registry Charitable Gala
June 10, 2024 12:01 ET
|
Gift of Life Marrow Registry
Gift of Life Marrow Registry hosted its One Huge Night NYC Gala, where two life-saving marrow donors were united with their transplant recipients.
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
May 02, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has...